Outcome of patients treated with third-line TKI according to the cytogenetic response obtained with the prior TKI therapy and to the cyto-genetic response obtained after 3 months on third-line therapy. The 14 patients who achieved at least MiCyR on imatinib or on second-line therapy (solid line) had a significantly better probability of achieving CCyR (A) and a better OS (B) on third-line nilotinib or dasatinib than the 12 patients who had primary cytogenetic resistance to the prior 2 lines of TKI therapy (broken line). The 30-month cumulative incidence of CCyR for the 2 groups was of 71.4% vs 0% (P = .0005), and the 30-month OS was 72.7% vs 20.4% (P = .03). When we excluded the only patient who died of nonleukemia-related reasons and in CCyR the OS were 90.1% vs 20.4% (P = .01). The 14 patients who achieved at least MiCyR on one of the prior TKI therapies also had a better EFS that the 14 patients with primary cytogenetic resistance, specifically 70.5% vs 16.2% (P = .02). (C-D) Results of the landmark analyses for the achievement of CCyR and OS (excluding the nonleukemia-related death) according to the cytogenetic response at 3 months on nilotinib or dasatinib as third-line therapy. At 3 months, 9 patients had achieved at least MiCyR (solid line). These patients had higher probabilities of achieving CCyR (C) and OS (D) than the 17 patients who had failed to do so (broken line), specifically 88.9% vs 13.3% (P < .0001), and 100% vs 35.0% (P = .04; see text).